Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Research & Development (2018 - 2025)

10x Genomics (TXG) has disclosed Research & Development for 8 consecutive years, with $56.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 16.42% to $56.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $238.6 million through Dec 2025, down 9.85% year-over-year, with the annual reading at $238.6 million for FY2025, 9.85% down from the prior year.
  • Research & Development hit $56.0 million in Q4 2025 for 10x Genomics, down from $57.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $71.5 million in Q2 2023 to a low of $41.9 million in Q1 2021.
  • Historically, Research & Development has averaged $62.6 million across 5 years, with a median of $64.2 million in 2022.
  • Biggest five-year swings in Research & Development: surged 93.94% in 2021 and later decreased 16.42% in 2025.
  • Year by year, Research & Development stood at $61.9 million in 2021, then rose by 2.79% to $63.6 million in 2022, then increased by 2.6% to $65.3 million in 2023, then rose by 2.61% to $67.0 million in 2024, then dropped by 16.42% to $56.0 million in 2025.
  • Business Quant data shows Research & Development for TXG at $56.0 million in Q4 2025, $57.2 million in Q3 2025, and $61.2 million in Q2 2025.